- Anatara Life’s (ANR) 200-patient Gastrointestinal ReProgramming (GaRP) trial gains momentum, with enrolments back on track after ANR’s festive season break
- The company expects to finish recruitment for the first phase of the trial early in the second quarter of 2023, with roughly 50 of 90 patients already enrolled
- This means the company is on track for an interim read-out of results for the irritable bowel syndrome (IBS) study in the third quarter of the year
- Meanwhile, Antara signs an agreement with healthcare company Mucpharm to use ANR’s licenced technology in mucin-producing cancers and biofilms
- ANR shares are trading grey at 2.8 cents at 1:37 pm AEDT
Anatara Life’s (ANR) 200-patient Gastrointestinal ReProgramming (GaRP) trial had gained momentum, with enrolments back on track after ANR’s festive season break.
A delay in the recruitment and randomisation of the GaRP trial from mid-December to early 2023 had been anticipated by ANR, although the company said product and placebo trials were back on track again last week.
As such, ANR said it expected to finish recruitment for the first phase of the trial early in the second quarter of 2023, with roughly 50 of 90 patients already enrolled.
This means the company is on track for an interim read-out of results for the irritable bowel syndrome (IBS) study in the third quarter of the year.
Antara said there was a “high prevalence” of digestive disorders requiring relief from both symptoms and the disease process, and the company was focused on building a pipeline of human gastrointestinal health products.
ANR noted there had been no significant tolerance or safety issues to date for its product, and it was experiencing a higher enrolment rate since fixing screen failure inconsistencies.
ANR is currently seeking a site in South Australia for the GaRP-IBS trial stage two while considering the geographical convenience of potential participants.
ANR said the GaRP IBS trial presented a significant market opportunity for non-prescription products used in gastrointestinal disorders and IBS, valued at US$8 billion (A$12.1 billion).
Meanwhile, Anatara has signed an agreement with private healthcare company Mucpharm to allow the utilisation of ANR’s licenced technology for specific fields of interest, including mucin-producing cancers and biofilms.
Mucpharm is a specialised company focused on the treatment of mucin-containing and secreting conditions, and the agreement will provide Anatara with royalties on sales and sub-licencing.
ANR shares are trading grey at 2.8 cents at 1:37 pm AEDT.